PMID- 15527675
OWN - NLM
STAT- MEDLINE
DCOM- 20041230
LR  - 20191109
IS  - 1522-8037 (Print)
IS  - 1522-8037 (Linking)
VI  - 6
IP  - 6
DP  - 2004 Dec
TI  - Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated 
      inherited disorders, and acid hypersecretion.
PG  - 454-63
AB  - Despite general awareness of Zollinger-Ellison syndrome (ZES) by most physicians 
      and more than 3000 articles written about it since 1955, the diagnosis of ZES is 
      still delayed for a mean of 5 years. Recent studies show it is being delayed even 
      more with the widespread use of proton pump inhibitors. A number of tumor 
      markers, in addition to assessing serum gastrin, such as chromogranin A, 
      neuron-specific enolase, and subunits of chorionic gonadotropin, have been 
      proposed for use in either the diagnosis of pancreatic endocrine tumors, such as 
      gastrinomas, or for assessment of tumor extent and growth. In this article 
      important recent insights into the diagnosis of ZES as well as the clinical 
      usefulness of assessing tumor markers for diagnosis and determination of disease 
      extent and growth are discussed. Approximately 25% of ZES cases are due to 
      multiple endocrine neoplasia type 1 (MEN1). A number of important studies in this 
      group of patients are also reviewed. Finally, almost every patient with ZES has 
      marked gastric acid hypersecretion, and its current treatment as well as the 
      long-term possible side effects are reviewed briefly.
FAU - Gibril, Fathia
AU  - Gibril F
AD  - Digestive Diseases Branch, National Institute of Diabetes and Digestive and 
      Kidney Diseases, National Institutes of Health, Building 10, Room 9C-103, 10 
      Center Drive MSC 1804, Bethesda, MD 20892-1804, USA.
FAU - Jensen, Robert T
AU  - Jensen RT
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Gastroenterol Rep
JT  - Current gastroenterology reports
JID - 100888896
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chorionic Gonadotropin)
RN  - 0 (Chromogranin A)
RN  - 0 (Chromogranins)
RN  - 0 (Gastrins)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - EC 4.2.1.11 (Phosphopyruvate Hydratase)
RN  - RWM8CCW8GP (Octreotide)
SB  - IM
MH  - Algorithms
MH  - Biomarkers, Tumor/blood
MH  - Carcinoid Tumor/diagnosis
MH  - Chorionic Gonadotropin/blood
MH  - Chromogranin A
MH  - Chromogranins/blood
MH  - Gastric Acid/metabolism
MH  - Gastrinoma/diagnosis
MH  - Gastrins/blood
MH  - Gastrointestinal Agents
MH  - Humans
MH  - Hyperparathyroidism/diagnosis
MH  - Multiple Endocrine Neoplasia Type 1/etiology
MH  - Octreotide
MH  - Pancreatic Neoplasms/diagnosis
MH  - Phosphopyruvate Hydratase/blood
MH  - Proton Pump Inhibitors
MH  - Stomach Neoplasms/diagnosis
MH  - Zollinger-Ellison Syndrome/complications/*diagnosis
RF  - 71
EDAT- 2004/11/06 09:00
MHDA- 2004/12/31 09:00
CRDT- 2004/11/06 09:00
PHST- 2004/11/06 09:00 [pubmed]
PHST- 2004/12/31 09:00 [medline]
PHST- 2004/11/06 09:00 [entrez]
AID - 10.1007/s11894-004-0067-5 [doi]
PST - ppublish
SO  - Curr Gastroenterol Rep. 2004 Dec;6(6):454-63. doi: 10.1007/s11894-004-0067-5.